// App-Quantinova.ai

594 : Complement Blockade With a C1 Esterase Inhibitor In Paroxysmal Nocturnal Hemoglobinuria

Researchers

Presenter

  • Amy E. DeZern

Principal Investigators

  • Marc Uknis

  • Galina Mukhina

  • Jo Anne Saye

  • Jeffrey J Pu

  • Robert Brodsky

Medical Centers

  • Johns Hopkins University School of Medicine, Baltimore, MD

  • Penn State Hershey Cancer Institute, Department of Medicine (Hematology/Oncology), Penn State College of Medicine, Hershey, PA.

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Division of Surgical Oncology, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD

Locations

  • United States

Companies

  • Shire ViroPharma Inc

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

  • Hereditary angioedema

  • Hemolytic anemia, CD59-mediated, with or without polyneuropathy

  • C1 Inhibitor Deficiency

  • Venous thrombosis

  • Anemia

Biomarkers

  • Cluster of Differentiation 55

  • Cluster of differentiation 59

  • Glycosylphosphatidylinositol

  • Soluble Complement 5b-9

Drug/Treatment

  • Eculizumab

  • Cinryze

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved